Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 157

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 157
---
. Our actual results may not always be in line with or exceed any guidance we have provided, especially in times of economic uncertainty. If, in the future, our operating or financial results for a particular period do not meet any guidance we provide or the expectations of investment analysts, or if we reduce our guidance for future periods, the market price of the Company Shares may decline. The listing of the Company’s securities on Nasdaq will not benefit from the process undertaken in connection with an underwritten initial public offering. Upon the Closing, the Company intends to list the Company Shares and the Company Warrants on Nasdaq under the symbols “OMNI” and “OMNIW,” respectively. Unlike the underwritten initial public offering of APx’s securities, the initial listing of the Company’s securities as a result of the Business Combination will not benefit from the following: •the book -buildingprocess undertaken by underwriters that helps to inform efficient price discovery with respect to opening trades of newly listed securities; •underwriter support to help stabilize, maintain or affect the public price of the new issue immediately after listing; or •underwriter due diligence review of the offering and potential liability for material misstatements or omissions of fact in a prospectus used in connection with the securities being offered or for statements made by its securities analysts or other personnel (consistent with applicable SEC rules and regulations currently in effect on the date hereof). The lack of such a process in connection with the listing of the Company’s securities could result in diminished investor demand, inefficiencies in pricing and a more volatile public price for the Company’s securities during the period immediately following the listing than in connection with an underwritten initial public offering. Risks Related to Our Intellectual Property We primarily rely and expect to rely in the future on trade secrets, copyrights, trademarks, know -how , patents and other forms of intellectual property protections, and if such protections are not adequate our business may be adversely affected. The proprietary positions of companies developing tools for the life sciences, genomics, forensics and pharmaceutical industries generally are uncertain and involve complex legal and factual questions. We rely and expect to rely in the future upon trade secrets, copyrights, trademarks, know -how, patents and other forms of intellectual property protections, to protect our confidential and proprietary information. In addition, we rely and expect to rely in the future upon trade secret protection to protect unpatented know -howand continuing technological innovation, in particular since OmnigenicsAI has not filed any patent applications in any jurisdiction. We have or may acquire